Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring Circulating Tumor DNA and Evaluating Prognostic and Predictive Impact of Liquid Biopsy in Advanced HER2 Negative Gastric Cancer

NCT05513144 is registered in ClinicalTrials.gov with chenwu as lead sponsor.

NCT NCT05513144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05513144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring Circulating Tumor DNA and Evaluating Prognostic and Predictive Impact of Liquid Biopsy in Advanced HER2 Negative Gastric Cancer
Lead sponsor
chenwu
Phase
Observational
Overall status
Unknown status
Start date
December 24, 2021
Completion date
February 28, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor dna (ctdna), gastric cancer